PRK vs STAA: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PRK is the larger of the two ($3.07B market cap): the incumbent the market prices for continued execution (12.92x forward earnings, beta 0.71). STAA is the smaller challenger ($1.21B), actually pricier on forward earnings (21.26x): more room to run, but more to prove. If you believe STAA earns its premium (21.26x forward earnings, so the market expects more from it), STAA fits. If you believe in paying less for profit, PRK fits at 12.92x.

PRK vs STAA: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricPRKSTAAWhat it tells you
Market cap$3.07B$1.21BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E12.9221.26Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E14.892,408.00Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.711.20Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range31% of range42% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.793.21How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: PRK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how PRK and STAA affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. PRK and STAA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined PRK and STAA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Park National Corporation (PRK) do?

Park National Corporation (NYSE American: PRK) is a financial holding company headquartered in Newark, Ohio, with about $12.65 billion in assets as of September 30, 2026. It operates through its wholly owned subsidiary, The Park National Bank, offering commercial banking, consumer banking, and wealth management (trust and investment) services primarily across Ohio and neighboring Midwest markets. On February 1, 2026, Park completed an all-stock acquisition of First Citizens Bancshares, a Tennessee bank with about $2.6 billion in assets, expanding its geographic footprint and loan book.

Full PRK guide

What does STAAR Surgical (STAA) do?

STAAR Surgical, based in Lake Forest, California, makes implantable lenses for vision correction. Its main product is the EVO Implantable Collamer Lens (ICL), a soft lens that a surgeon slips behind the iris and in front of the eye's natural lens, correcting myopia, with or without astigmatism, without removing corneal tissue the way LASIK or SMILE do. The lens can be taken out later. It is sold in more than 75 countries, gained U.S. FDA approval in its EVO form in 2022, and is manufactured in Monrovia, California and in Switzerland. Nearly all revenue comes from the ICL family, including the newer EVO+ with a larger optic and toric versions for astigmatism.

Full STAA guide

PRK vs STAA: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • PRK drivers: First Citizens integration and scale; Net interest income and margins.
  • STAA drivers: China demand and pricing; Growth outside China.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: As a spread lender, Park is exposed to interest-rate swings that can compress net interest margins if deposit costs rise faster than loan yields. For STAA, close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return.

PRK or STAA: which should you pick?

If the story you believe is PRK's (First Citizens integration and scale), PRK is the more direct way to own it; if it is STAA's (China demand and pricing), STAA is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the PRK and STAA guides.

PRK vs STAA: the full fundamentals

PRK. At about $170 a share Park trades near 15 times trailing and 13 times forward earnings and about 1.8 times book, still a premium to average regional banks that reflects its consistent profitability and credit quality, though narrower than in October after the three-month pullback. Earnings have stepped up since the second quarter of 2026 as the First Citizens acquisition fed through, after a first quarter dampened by around $15.5 million of merger-related expenses. Analysts expect about $13.01 of EPS for 2026 and $13.14 for 2027, and four analysts carry an average target near $199.50.

STAA. Trailing revenue of about $328 million combines the weak fourth quarter of 2025 (~$57.8 million and an ~$18.3 million loss) with three strong 2026 quarters, so the trailing GAAP profit of roughly zero understates the current run rate. Taking off the cash, enterprise value is about $1.0 billion, around 3.1 times trailing sales and about 13 times nine-month adjusted EBITDA annualized; the forward P/E is about 21 on 2027 EPS estimates near $1.13. The shares sit about 22% below Alcon's rejected $30.75 offer and under the ~$28.56 mean analyst target, with a Buy average from nine analysts.

Headline figures (approximate, November 2026): PRK shows revenue (ttm) ~$649 million, up ~30% year over year in Q3 2026, net income (ttm) ~$200 million; profit margin ~31%, latest quarter (q3 2026) Net income ~$56.9 million; diluted EPS ~$3.13; adjusted EPS ~$3.37 vs ~$3.31 estimate, net interest income (q3 2026) ~$140.7 million, up ~27%; net interest margin ~4.84%; STAA shows revenue (ttm through q3 2026) ~$328M, net income (ttm through q3 2026) ~breakeven (~$18.8M for 9M 2026), adjusted ebitda (9m 2026) ~$58.8M, gross margin (q3 2026) ~70.9% (82.2% a year earlier).

The bottom line: PRK vs STAA

PRK and STAA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined PRK and STAA exposure against your real portfolio. It is not an investment adviser.

Wondering how PRK or STAA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Park National Corporation

Ask Walnut's AI anything about PRK and see how it fits what you own.

FAQ

What is the difference between PRK and STAA?

+

Park National Corporation (NYSE American: PRK) is a financial holding company headquartered in Newark, Ohio, with about $12.65 billion in assets as of September 30, 2026. STAAR Surgical, based in Lake Forest, California, makes implantable lenses for vision correction. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is PRK or STAA the better stock?

+

Neither is universally better. PRK is the larger incumbent; STAA is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, PRK or STAA?

+

On forward P/E (as of November 2026), PRK trades at 12.92x and STAA at 21.26x, so PRK is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both PRK and STAA?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of PRK vs STAA?

+

PRK: As a spread lender, Park is exposed to interest-rate swings that can compress net interest margins if deposit costs rise faster than loan yields. Its concentration in Ohio and now Tennessee makes it sensitive to regional economic conditions, commercial real estate exposure, and local credit cycles. Integration risk from the First Citizens deal is real, as merger costs and any operational missteps can pressure near-term earnings; the third-quarter efficiency ratio of about 60% drew attention after the report and the shares stalled. Broader banking-sector stress, deposit competition, and regulatory or capital-requirement changes are additional headwinds. Finally, as a slower-growth community bank, the stock offers limited upside surprise relative to faster-growing financials. The stock trades near 15 times trailing earnings after falling about 15% over three months, and analysts expect EPS growth to slow to about 1% in 2027 once the merger is fully in the base, so the valuation still leaves limited room for a credit or margin disappointment. STAA: Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Chinese competition is now real. Eyebright Medical's Loong Crystal PR phakic lens was approved by China's NMPA in January 2025, and a small Fudan University study found similar efficacy and safety against the EVO ICL in paired eyes. Hospital procurement policy in China, including volume-based purchasing that has squeezed prices for cataract lenses, could reach phakic lenses. Tariffs already cut third-quarter gross margin by several points, and U.S.-origin product sold into China is still subject to them. Japan and South Korea are declining. The ICL is effectively the whole company, so a safety signal, a recall or a manufacturing problem at either plant would hit every line of the income statement. Finally, the share price no longer has a takeover floor. Holders who rejected $30.75 are relying on the standalone plan, and the stock has traded between ~$15.59 and ~$35.87 over the past 52 weeks.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell PRK or STAA; figures are approximate and dated (as of November 2026). Verify current data before investing.